Calgary, Alberta – TheNewswire - December 9, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, is pleased to announce that Medicel AG (“Medicel”), a global leader in ophthalmic device delivery systems, has further modified its lens delivery technology in response to surgeon input following first-in-human lens implantation procedures. “The surgeon who performed our first-in-human implantations has bee ...

Core Insights - Ocumetics Technology Corp. has successfully implanted its innovative accommodating intraocular lens in human subjects, marking a significant milestone in vision correction technology [1][2][3] - The Ocumetics Lens aims to restore dynamic vision for patients, particularly those undergoing cataract surgery, by allowing clear vision at all distances without the need for glasses or contact lenses [3][7] - The company is committed to continuing its clinical trial program to validate the safety and performance of the Ocumetics Lens, which is expected to lead to regulatory approvals and broader clinical use [4][5] Company Overview - Ocumetics Technology Corp. is a Canadian research and product development company focused on advanced vision correction solutions to enhance patients' quality of life [6] - The company has been dedicated to innovation in ophthalmology for nearly two decades, with a strong emphasis on developing state-of-the-art intraocular lenses [2][6] Industry Impact - The Ocumetics Lens has the potential to reshape the global standard of care for cataract and presbyopia patients, addressing the growing demand for better vision solutions due to aging populations [3][4] - The technology is designed to work with the natural movements of the eye, which could significantly improve patient outcomes compared to traditional lens options [3][7]

Core Insights - Ocumetics Technology Corp. has achieved a significant breakthrough in the development of next-generation intraocular lens technology, demonstrating accommodative power change in laboratory testing [1][2] - The company plans to prepare for first-in-human studies scheduled for summer 2025, following successful laboratory results [2][3] Company Overview - Ocumetics Technology Corp. is a Canadian research and product development company focused on advanced vision correction solutions aimed at enhancing patients' quality of life [4] - The company is dedicated to transforming the field of ophthalmology through innovative research and development of state-of-the-art intraocular lenses and other vision-enhancing technologies [4] Technological Development - The intraocular lens developed by Ocumetics is designed to fit within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses [5] - This lens allows the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the assistance of glasses or contact lenses [5] Research and Development - The testing utilized Ocumetics' Lens Analyzer (IOLA) bench testing platform to simulate ciliary body pressures, confirming the lens's ability to respond dynamically [2][3] - The company continues to collaborate with leading ophthalmic researchers, engineers, and clinical advisors to advance its rigorous R&D roadmap [3]